AVANOS MEDICAL INC (AVNS) Fundamental Analysis & Valuation

NYSE:AVNS • US05350V1061

Current stock price

24.66 USD
-0.05 (-0.2%)
At close:
24.66 USD
0 (0%)
After Hours:

This AVNS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. AVNS Profitability Analysis

1.1 Basic Checks

  • In the past year AVNS was profitable.
  • AVNS had a positive operating cash flow in the past year.
  • In multiple years AVNS reported negative net income over the last 5 years.
  • Each year in the past 5 years AVNS had a positive operating cash flow.
AVNS Yearly Net Income VS EBIT VS OCF VS FCFAVNS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M -200M -300M

1.2 Ratios

  • The Return On Assets of AVNS (-6.79%) is better than 67.38% of its industry peers.
  • AVNS has a better Return On Equity (-9.37%) than 68.98% of its industry peers.
  • With a decent Return On Invested Capital value of 1.47%, AVNS is doing good in the industry, outperforming 68.98% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for AVNS is significantly below the industry average of 9.12%.
Industry RankSector Rank
ROA -6.79%
ROE -9.37%
ROIC 1.47%
ROA(3y)-14.8%
ROA(5y)-8.25%
ROE(3y)-20.56%
ROE(5y)-11.47%
ROIC(3y)1.82%
ROIC(5y)2.02%
AVNS Yearly ROA, ROE, ROICAVNS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10 -20 -30 -40

1.3 Margins

  • The Operating Margin of AVNS (2.41%) is better than 67.91% of its industry peers.
  • AVNS's Operating Margin has declined in the last couple of years.
  • Looking at the Gross Margin, with a value of 50.47%, AVNS is in line with its industry, outperforming 45.99% of the companies in the same industry.
  • In the last couple of years the Gross Margin of AVNS has remained more or less at the same level.
Industry RankSector Rank
OM 2.41%
PM (TTM) N/A
GM 50.47%
OM growth 3Y-36.17%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.75%
GM growth 5Y-0.68%
AVNS Yearly Profit, Operating, Gross MarginsAVNS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. AVNS Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so AVNS is destroying value.
  • The number of shares outstanding for AVNS has been increased compared to 1 year ago.
  • AVNS has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for AVNS has been reduced compared to a year ago.
AVNS Yearly Shares OutstandingAVNS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
AVNS Yearly Total Debt VS Total AssetsAVNS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • An Altman-Z score of 2.23 indicates that AVNS is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • AVNS has a Altman-Z score of 2.23. This is in the better half of the industry: AVNS outperforms 61.50% of its industry peers.
  • AVNS has a debt to FCF ratio of 2.33. This is a good value and a sign of high solvency as AVNS would need 2.33 years to pay back of all of its debts.
  • AVNS has a Debt to FCF ratio of 2.33. This is amongst the best in the industry. AVNS outperforms 84.49% of its industry peers.
  • A Debt/Equity ratio of 0.12 indicates that AVNS is not too dependend on debt financing.
  • AVNS's Debt to Equity ratio of 0.12 is fine compared to the rest of the industry. AVNS outperforms 64.17% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 2.33
Altman-Z 2.23
ROIC/WACC0.17
WACC8.52%
AVNS Yearly LT Debt VS Equity VS FCFAVNS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

2.3 Liquidity

  • A Current Ratio of 2.15 indicates that AVNS has no problem at all paying its short term obligations.
  • AVNS has a Current ratio of 2.15. This is comparable to the rest of the industry: AVNS outperforms 41.18% of its industry peers.
  • AVNS has a Quick Ratio of 1.26. This is a normal value and indicates that AVNS is financially healthy and should not expect problems in meeting its short term obligations.
  • AVNS has a worse Quick ratio (1.26) than 68.98% of its industry peers.
Industry RankSector Rank
Current Ratio 2.15
Quick Ratio 1.26
AVNS Yearly Current Assets VS Current LiabilitesAVNS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. AVNS Growth Analysis

3.1 Past

  • The earnings per share for AVNS have decreased strongly by -25.40% in the last year.
  • Measured over the past 5 years, AVNS shows a small growth in Earnings Per Share. The EPS has been growing by 3.80% on average per year.
  • The Revenue has been growing slightly by 1.95% in the past year.
  • Measured over the past years, AVNS shows a decrease in Revenue. The Revenue has been decreasing by -0.38% on average per year.
EPS 1Y (TTM)-25.4%
EPS 3Y-17.1%
EPS 5Y3.8%
EPS Q2Q%-30.95%
Revenue 1Y (TTM)1.95%
Revenue growth 3Y-5.08%
Revenue growth 5Y-0.38%
Sales Q2Q%0.72%

3.2 Future

  • The Earnings Per Share is expected to grow by 16.51% on average over the next years. This is quite good.
  • Based on estimates for the next years, AVNS will show a small growth in Revenue. The Revenue will grow by 3.19% on average per year.
EPS Next Y8.62%
EPS Next 2Y16.51%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2.16%
Revenue Next 2Y3.19%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AVNS Yearly Revenue VS EstimatesAVNS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B
AVNS Yearly EPS VS EstimatesAVNS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

4

4. AVNS Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 26.23, the valuation of AVNS can be described as expensive.
  • Based on the Price/Earnings ratio, AVNS is valued a bit cheaper than 72.73% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.42, AVNS is valued at the same level.
  • The Price/Forward Earnings ratio is 24.15, which indicates a rather expensive current valuation of AVNS.
  • Based on the Price/Forward Earnings ratio, AVNS is valued a bit cheaper than 75.94% of the companies in the same industry.
  • AVNS is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.24, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 26.23
Fwd PE 24.15
AVNS Price Earnings VS Forward Price EarningsAVNS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AVNS indicates a somewhat cheap valuation: AVNS is cheaper than 73.80% of the companies listed in the same industry.
  • 81.28% of the companies in the same industry are more expensive than AVNS, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 26.61
EV/EBITDA 20.75
AVNS Per share dataAVNS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates AVNS does not grow enough to justify the current Price/Earnings ratio.
  • A more expensive valuation may be justified as AVNS's earnings are expected to grow with 16.51% in the coming years.
PEG (NY)3.04
PEG (5Y)6.9
EPS Next 2Y16.51%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AVNS Dividend Analysis

5.1 Amount

  • AVNS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AVNS Fundamentals: All Metrics, Ratios and Statistics

AVANOS MEDICAL INC

NYSE:AVNS (4/24/2026, 8:22:16 PM)

After market: 24.66 0 (0%)

24.66

-0.05 (-0.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-24
Earnings (Next)05-04
Inst Owners97.14%
Inst Owner Change-0.16%
Ins Owners4.67%
Ins Owner Change5.19%
Market Cap1.15B
Revenue(TTM)701.20M
Net Income(TTM)-72.90M
Analysts43.33
Price TargetN/A
Short Float %4.93%
Short Ratio3.82
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.19%
Min EPS beat(2)14.64%
Max EPS beat(2)79.74%
EPS beat(4)4
Avg EPS beat(4)36.78%
Min EPS beat(4)11.11%
Max EPS beat(4)79.74%
EPS beat(8)5
Avg EPS beat(8)16.95%
EPS beat(12)7
Avg EPS beat(12)15.54%
EPS beat(16)10
Avg EPS beat(16)13.47%
Revenue beat(2)2
Avg Revenue beat(2)3.74%
Min Revenue beat(2)1.52%
Max Revenue beat(2)5.97%
Revenue beat(4)4
Avg Revenue beat(4)3.17%
Min Revenue beat(4)1.52%
Max Revenue beat(4)5.97%
Revenue beat(8)4
Avg Revenue beat(8)0.74%
Revenue beat(12)4
Avg Revenue beat(12)-0.83%
Revenue beat(16)4
Avg Revenue beat(16)-4.39%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-39.13%
EPS NY rev (1m)0%
EPS NY rev (3m)5.37%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.29%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 26.23
Fwd PE 24.15
P/S 1.64
P/FCF 26.61
P/OCF 15.35
P/B 1.47
P/tB 4.32
EV/EBITDA 20.75
EPS(TTM)0.94
EY3.81%
EPS(NY)1.02
Fwd EY4.14%
FCF(TTM)0.93
FCFY3.76%
OCF(TTM)1.61
OCFY6.51%
SpS15.08
BVpS16.73
TBVpS5.71
PEG (NY)3.04
PEG (5Y)6.9
Graham Number18.8117 (-23.72%)
Profitability
Industry RankSector Rank
ROA -6.79%
ROE -9.37%
ROCE 1.86%
ROIC 1.47%
ROICexc 1.63%
ROICexgc 4.36%
OM 2.41%
PM (TTM) N/A
GM 50.47%
FCFM 6.15%
ROA(3y)-14.8%
ROA(5y)-8.25%
ROE(3y)-20.56%
ROE(5y)-11.47%
ROIC(3y)1.82%
ROIC(5y)2.02%
ROICexc(3y)2.02%
ROICexc(5y)2.23%
ROICexgc(3y)5.81%
ROICexgc(5y)7.12%
ROCE(3y)2.3%
ROCE(5y)2.56%
ROICexgc growth 3Y-33.59%
ROICexgc growth 5YN/A
ROICexc growth 3Y-26.31%
ROICexc growth 5YN/A
OM growth 3Y-36.17%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.75%
GM growth 5Y-0.68%
F-Score6
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 2.33
Debt/EBITDA 1.62
Cap/Depr 81.23%
Cap/Sales 4.51%
Interest Coverage 2.6
Cash Conversion 133.87%
Profit Quality N/A
Current Ratio 2.15
Quick Ratio 1.26
Altman-Z 2.23
F-Score6
WACC8.52%
ROIC/WACC0.17
Cap/Depr(3y)52.99%
Cap/Depr(5y)50.85%
Cap/Sales(3y)3.25%
Cap/Sales(5y)2.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25.4%
EPS 3Y-17.1%
EPS 5Y3.8%
EPS Q2Q%-30.95%
EPS Next Y8.62%
EPS Next 2Y16.51%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1.95%
Revenue growth 3Y-5.08%
Revenue growth 5Y-0.38%
Sales Q2Q%0.72%
Revenue Next Year2.16%
Revenue Next 2Y3.19%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-62.19%
EBIT growth 3Y-39.42%
EBIT growth 5YN/A
EBIT Next Year165.31%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-48.01%
FCF growth 3Y-15.57%
FCF growth 5YN/A
OCF growth 1Y-25.82%
OCF growth 3Y-6.33%
OCF growth 5YN/A

AVANOS MEDICAL INC / AVNS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for AVANOS MEDICAL INC?

ChartMill assigns a fundamental rating of 4 / 10 to AVNS.


What is the valuation status for AVNS stock?

ChartMill assigns a valuation rating of 4 / 10 to AVANOS MEDICAL INC (AVNS). This can be considered as Fairly Valued.


How profitable is AVANOS MEDICAL INC (AVNS) stock?

AVANOS MEDICAL INC (AVNS) has a profitability rating of 4 / 10.


What is the valuation of AVANOS MEDICAL INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for AVANOS MEDICAL INC (AVNS) is 26.23 and the Price/Book (PB) ratio is 1.47.


Can you provide the financial health for AVNS stock?

The financial health rating of AVANOS MEDICAL INC (AVNS) is 6 / 10.